K. Fujino

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

M. Schlumberger, K. Muro, Y. Ando, 2015, Cancer science.

Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors.

A. Ohtsu, T. Yoshino, M. Tahara, 2012 .

Lenvatinib for Anaplastic Thyroid Cancer

K. Nakano, M. Tahara, H. Minami, 2017, Front. Oncol..

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors

H. Wakui, T. Tamura, Yasuhide Yamada, 2015, Cancer Chemotherapy and Pharmacology.

Factors associated with variation in utility scores among patients with prostate cancer.

Y. Ohashi, T. Fukuda, S. Minowada, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.

M. Brose, L. Wirth, M. Tahara, 2019, European Journal of Cancer.

Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.

K. Nakano, M. Tahara, H. Minami, 2016 .

995PDPHASE II STUDY OF LENVATINIB (LEN), A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN PATIENTS (PTS) WITH ALL HISTOLOGIC SUBTYPES OF ADVANCED THYROID CANCER (DIFFERENTIATED, MEDULLARY AND ANAPLASTIC).

K. Nakano, M. Tahara, H. Minami, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.